Ingmar F Rompen
Overview
Explore the profile of Ingmar F Rompen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
71
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Habib J, Rompen I, Javed A, Campbell B, Kinny-Koster B, Tan P, et al.
Ann Surg
. 2025 Mar;
PMID: 40042799
Summary Of Background Data: Intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic cancer is typically managed like pancreatic intraepithelial neoplasia (PanIN)-derived pancreatic cancer. However, in IPMN-derived pancreatic cancer, the role of chemotherapy...
2.
Rompen I, Yilmazcelik B, Crnovrsanin N, Schiefer S, Jorek N, Kantowski M, et al.
Dis Esophagus
. 2025 Feb;
38(1).
PMID: 39981709
Early delayed gastric conduit emptying (DGCE) is a frequent complication after Ivor-Lewis esophagectomy (ILE). Despite its relevance, few studies are published using the international consensus criteria. Therefore, we aimed to...
3.
Javed A, Habib J, Andel P, Campbell B, Rompen I, Mahmud O, et al.
Ann Surg
. 2025 Feb;
PMID: 39928537
Objective: The aim of the study was to investigate prognostic factors in context of neoadjuvant therapy (NAT) and develop tools that can allow for accurate and personalized patient prognostication. Summary...
4.
Rompen I, Stoop T, van Roessel S, van Veldhuisen E, Janssen Q, Alseidi A, et al.
Ann Surg
. 2025 Jan;
PMID: 39886770
Aim: To validate the prognostic value of the PAncreatic NeoAdjuvant MAssachusetts (PANAMA)-score and to determine its predictive ability for survival benefit derived from adjuvant treatment in patients after resection of...
5.
Schiefer S, Crnovrsanin N, Rompen I, Jorek N, Al-Saeedi M, Schmidt T, et al.
J Cancer Res Clin Oncol
. 2025 Jan;
151(2):51.
PMID: 39875671
Purpose: Oncological esophagectomy is the mainstay in esophageal cancer treatment, but perioperative mortality remains a significant concern. Various scoring systems exist to identify patients at high risk for postoperative complications...
6.
Habib J, Rompen I, Hidalgo Salinas C, Groot V, Javed A, Daamen L
Ann Surg Oncol
. 2025 Jan;
32(4):2868-2869.
PMID: 39853482
No abstract available.
7.
Stoop T, Molnar A, Seelen L, Sugawara T, Scheepens J, Ali M, et al.
Ann Surg
. 2025 Jan;
PMID: 39846439
Objective: To investigate whether tangential versus segmental portomesenteric venous resection (PVR) impacts surgical and oncological outcome in patients undergoing pancreatoduodenectomy for pancreatic cancer with portomesenteric vein (PMV) involvement. Summary Background...
8.
Rompen I, Marchetti A, Levine J, Swett B, Galimberti V, Han J, et al.
Surgery
. 2025 Jan;
180():109114.
PMID: 39798179
Background: To improve outcomes for patients with pancreatic ductal adenocarcinoma, a complete resection is crucial. However, evidence regarding the impact of microscopically positive surgical margins (R1) on recurrence is conflicting...
9.
Habib J, Javed A, Rompen I, Hidalgo Salinas C, Sorrentino A, Campbell B, et al.
Ann Surg Oncol
. 2025 Jan;
32(3):1911-1912.
PMID: 39755887
No abstract available.
10.
Habib J, Javed A, Rompen I, Hidalgo Salinas C, Sorrentino A, Campbell B, et al.
Ann Surg Oncol
. 2024 Dec;
32(3):1879-1886.
PMID: 39666193
Background: Early recurrence in intraductal papillary mucinous neoplasm (IPMN)-derived pancreatic ductal adenocarcinoma (PDAC) is poorly defined. Predictors are lacking and needed for patient counseling, risk stratification, and postoperative management. This...